MeCure eyes N10bn from series 7 Commercial Paper issuance

MeCure Industries Plc (MeCure) has opened a N10 billion Series 7 Commercial Paper (CP)Issuance under its N40 billion Commercial Paper (CP) Programme. The offer is now open and scheduled to close on Friday, February 20.

The leading human therapeutics company in the Nigerian pharmaceutical industry, recently converted to a Public Limited Company Plc and listed its shares on the NGX trading platform, fulfilling its promise to investors which includes substantial share price increase, reflecting strong investor confidence, and raising the total market capitalisation to a new high.

In October 2024, there was a successful acquisition of a 10 percent equity stake in the company by Zrosk Investment Management Limited. This investment will boost Mecure’s financial position and fast track its growth strategy.

With Zrosk, Mecure is well positioned to drive forward its ambitious expansion plans and further contribute to the healthcare sector in Nigeria and beyond. The acquisition will help Mecure enhance its operational efficiencies and gain greater access to resources, positioning it for a stronger market presence.

MeCure has for close to two decades significantly advanced the pharmaceutical manufacturing sector in Nigeria through technology and innovation, pioneering novel products such as the Liquitab Floatcap, the industry’s first tablet-in-a-capsule formulation.

Related News

In October 2023, MeCure commenced the installation of its Beta-Lactam plant for manufacturing beta-lactam tablets and dry syrup, including combination antibiotics such as Amoxicillin-Clavulanic acid (Amoxyclav), a leading antibiotic for bacterial infections with a market size exceeding N500 billion.

Following the recent implementation of the Presidential Executive Order granting duty waivers to select pharmaceutical companies including MeCure Industries Plc. to boost local production of healthcare Products, the company is now sourcing all raw and packaging materials from China and India to fully leverage the benefits of this policy.

The company’s stable and experienced executive management team has a history of consistent superior financial performance and returns. In Q3 2025, Revenue increased to N60 billion (+98.5 percent year-on-year; Q3 2024: N30.2 billion) due to increase in the sales of finished products.

The company reported an operating profit of N13.02 billion in Q3 2025, an increase of 159 percent from N5.03 billion recorded in Q3 2024. MeCure Industries Plc has a stable outlook with short-term ratings of A1 DataPro and A3 by GCR, demonstrating its financial stability and commitment to delivering exceptional value to stakeholders in the pharmaceutical industry.

Iheanyi Nwachukwu

Iheanyi Nwachukwu, is a creative content writer with almost two decades journalism experience writing on banking, finance, capital markets, and tax. The multiple awards winning journalist is Assistant Editor, BusinessDay. Iheanyi holds BSc Degree in Economics from Imo State University; Master of Science (MSc) Degree in Management from University of Lagos. Iheanyi has attended several work-related trainings including (i) Advanced Writing and Reporting Skills (Pan African University, Lagos); (ii) News Agency Journalism (Indian Institute of Mass Communication {IIMC}, New Delhi, India); and (iii) Capital Markets Development and Regulations (International Law Institute {ILI} of Georgetown University, Washington DC, USA). Other trainings Iheanyi attended include: Economic/Political Risk Analysis (By Thomson Reuters Foundation); International Financial Journalism (IFJ) (By PMA Media Training, UK); Effective Business Writing Skills (By Phillips Consulting); Reporting on Corporate Governance (By International Finance Corporation (IFC) & Thomson Reuters Foundation UK); etc. In addition, he has participated in high-level economy & markets events in Dubai, South Africa, Morocco, and other African countries like Zambia, Ghana and Gambia.